Notice of Results and Business Update

Verici Dx PLC

11 July 2024

 

Verici Dx plc

("Verici Dx" or the "Company")

Notice of Results and Business Update

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it will report its interim results for the six months to 30 June 2024, together with a business update, on 15 July 2024.

Investor roadshow and briefings

Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live online presentation via the Investor Meet Company platform on Tuesday 16th July 2024 at 16:30 BST. This presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00 am BST the day before the meeting or during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

The Company will also be presenting in person at The Novotel, London on Wednesday 17 July 2024 at 18.00 BST as part of the regular series of "Shares" investor events hosted by AJ Bell. Existing shareholders and potential investors can register to attend this live evening event for free at: Shares Magazine - Events

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	[e-mail]
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Phil Davies / Sam Butcher

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END